Direct oral anticoagulants for the treatment of Mondor's disease not responding to low-molecular weight heparin.
Alessandra SerraoBenedetta LucaniErminia BaldacciLuciano FioriAntonio ChistoliniPublished in: Phlebology (2020)
Mondor's disease is a rare condition and usually treated with low-molecular weight heparin and non-steroidal anti-inflammatory drugs. Because of paucity of cases and for the usually spontaneous resolution, there is not a standard treatment strategy and the use of oral anticoagulation in controversial. We reported the efficacy of direct oral anticoagulants in the recurrent Mondor's disease refractory to standard therapy.